scholarly journals Selective impairment in dendritic cell function and altered antigen-specific CD8+T-cell responses in diet-induced obese mice infected with influenza virus

Immunology ◽  
2009 ◽  
Vol 126 (2) ◽  
pp. 268-279 ◽  
Author(s):  
Alexia G. Smith ◽  
Patricia A. Sheridan ◽  
Raymond J. Tseng ◽  
John F. Sheridan ◽  
Melinda A. Beck
2012 ◽  
Vol 6 (1) ◽  
pp. 83-92 ◽  
Author(s):  
K Yadava ◽  
A Sichelstiel ◽  
I F Luescher ◽  
L P Nicod ◽  
N L Harris ◽  
...  

2014 ◽  
Vol 45 (2) ◽  
pp. 624-635 ◽  
Author(s):  
Even Fossum ◽  
Gunnveig Grødeland ◽  
Dorothea Terhorst ◽  
Anders A. Tveita ◽  
Elisabeth Vikse ◽  
...  

2020 ◽  
Vol 8 (1) ◽  
pp. e000329 ◽  
Author(s):  
Brenda De Keersmaecker ◽  
Sofie Claerhout ◽  
Javier Carrasco ◽  
Isabelle Bar ◽  
Jurgen Corthals ◽  
...  

BackgroundWe previously reported that dendritic cell-based mRNA vaccination plus ipilimumab (TriMixDC-MEL IPI) results in an encouraging rate of tumor responses in patients with pretreated advanced melanoma. Here, we report the TriMixDC-MEL IPI-induced T-cell responses detected in the peripheral blood.MethodsMonocyte-derived dendritic cells electroporated with mRNA encoding CD70, CD40 ligand, and constitutively active TLR4 (TriMix) as well as the tumor-associated antigens tyrosinase, gp100, MAGE-A3, or MAGE-C2 were administered together with IPI for four cycles. For 18/39 patients, an additional vaccine was administered before the first IPI administration. We evaluated tumor-associated antigen specific T-cell responses in previously collected peripheral blood mononuclear cells, available from 15 patients.ResultsVaccine-induced enzyme-linked immunospot assay responses detected after in vitro T-cell stimulation were shown in 12/15 patients. Immune responses detected in patients with a complete or partial response were significantly stronger and broader, and exhibited a higher degree of multifunctionality compared with responses in patients with stable or progressive disease. CD8+ T-cell responses from patients with an ongoing clinical response, either elicited by TriMixDC-MEL IPI or on subsequent pembrolizumab treatment, exhibited the highest degree of multifunctionality.ConclusionsTriMixDC-MEL IPI treatment results in robust CD8+ T-cell responses in a meaningful portion of stage III or IV melanoma patients, and obviously in patients with a clinical response. The levels of polyfunctional and multiantigen T-cell responses measured in patients with a complete response, particularly in patients evidently cured after 5+ years of follow-up, may provide a benchmark for the level of immune stimulation needed to achieve a durable clinical remission.Trial registration numberNCT01302496.


2004 ◽  
Vol 24 (6) ◽  
pp. 653-663 ◽  
Author(s):  
THOMAS PUTZ ◽  
REINHOLD RAMONER ◽  
HUBERT GANDER ◽  
ANDREA RAHM ◽  
GEORG BARTSCH ◽  
...  

2009 ◽  
Vol 182 (8) ◽  
pp. 4565-4571 ◽  
Author(s):  
Michael J. Palmowski ◽  
Mathew Parker ◽  
Kaushik Choudhuri ◽  
Christopher Chiu ◽  
Margaret F. C. Callan ◽  
...  

PLoS ONE ◽  
2011 ◽  
Vol 6 (8) ◽  
pp. e22939 ◽  
Author(s):  
Tania G. Rodríguez-Cruz ◽  
Shujuan Liu ◽  
Jahan S. Khalili ◽  
Mayra Whittington ◽  
Minying Zhang ◽  
...  

2006 ◽  
Vol 36 (11) ◽  
pp. 2951-2959 ◽  
Author(s):  
Nicole L. La Gruta ◽  
Peter C. Doherty ◽  
Stephen J. Turner

Sign in / Sign up

Export Citation Format

Share Document